Table 1 Baseline clinical characteristics of CRT responders versus non-responders
Variable | Responders | Non-Responders | P Value |
|---|---|---|---|
(n = 27) | (n = 13) | ||
Age, years | 61.5 ± 10 | 58.2 ± 15.2 | .444 |
Female gender, n (%) | 9 (33%) | 1 (8%) | .113 |
Heart rate, beats/min | 73.5 ± 11.5 | 79.6 ± 23.1 | .407 |
SBP, mm Hg | 121.8 ± 13 | 115.8 ± 18.6 | .273 |
DBP, mm Hg | 76 ± 8.3 | 70.5 ± 7.4 | .065 |
NYHA functional class III/IV | 23/4 | 8/5 | .685 |
Ischemic Etiology, n (%) | 7 (26%) | 5 (38%) | .709 |
QRS | |||
duration (ms) | 160.5 ± 24.1 | 158.3 ± 28.5 | .812 |
LBBB morphology, n (%) | 20 (74%) | 9 (69%) | .706 |
Mitral regurgitation > grade II, n (%) | 15 (56%) | 9 (77%) | .463 |
Hypertension, n (%) | 14 (52%) | 3 (23%) | .163 |
Diabetes, n (%) | 6 (22%) | 2 (15%) | 1.000 |
Renal insufficiency, n (%) | 3 (11%) | 1 (8%) | 1.000 |
Serum biomarkers | |||
CK-MB, U/L | 11.5 ± 4.07 | 10.83 ± 3.69 | .646 |
CK-MM, U/L | 53.4 ± 30.13 | 54 ± 31.79 | .958 |
Cre, μmol/L | 84.74 ± 41.04 | 88.62 ± 15.48 | .756 |
hs CRP, mg/L | 7.46 ± 15.96 | 3.27 ± 6.2 | .513 |
Uric acid, μmol/L | 425.44 ± 148.55 | 479.03 ± 168.72 | .340 |
NT-proBNP, pg/mL | 2684.83 ± 2658.35 | 2956.5 ± 2748.22 | .786 |
cTnT, ng/mL | 0.02 ± 0.02 | 0.03 ± 0.02 | .101 |
Medication, n (%) | |||
ACEI/ARBs | 15 (55%) | 7 (54%) | 1.000 |
Beta-blockers | 13 (48%) | 6 (46%) | 1.000 |
Diuretics and/or spironolactone | 13 (48%) | 6 (46%) | 1.000 |